Drugs / WTX212A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06106152 | Dec 2023 → Oct 2024 | lung cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT06026605 | Aug 2023 → Aug 2026 overdue | cancer of unknown primary site | Zhejiang University | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07269899 | Nov 2025 → Feb 2027 expected | cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WTX212A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06106152 ↗ |
| Action | Inhibit | “autologous red blood cell PD-1 inhibitor conjugate” NCT06106152 ↗ |
| Modality | Protein / enzyme biologic | “Erythrocyte-αPD-1 Antibody Conjugates” NCT07269899 ↗ |